Oculus – the German ophthalmic medical device manufacturer – has committed to support International Myopia Institute (IMI) efforts to advance the research and awareness of myopia to prevent future vision impairment and blindness.
Oculus’s sponsorship of the IMI comes at an exciting time in myopia research. The IMI recently published Volume two of the 2021 white papers and yearly digest in a special issue of the peer-reviewed Investigative Ophthalmology and Visual Science (IOVS) and is now releasing the IMI 2021 clinical summaries.
We are thrilled to have Oculus join in our mission to advance research, patient management and education in myopia
“We are thrilled to have Oculus join in our mission to advance research, patient management and education in myopia,” said IMI Executive Director, Dr Monica Jong. “Open collaboration and sharing of knowledge globally with eye care practitioners (ECPs) are critical to prevent future myopia-related vision impairment and blindness. We will continue to bring the latest, evidence-based information directly to all ECPs across the world which would not be possible without our industry supporters.”
Christian Kirchhübel, CEO of Oculus said, “We are delighted about the cooperation. Our mission at Oculus is to support eye care professionals around the world with cutting-edge, high-tech development. We love saving and improving vision and are known for our innovative and reliable measurement solutions.”
IMI Chair, Professor Serge Resnikoff also welcomed the sponsorship. “There remains much to do in terms of growing myopia awareness and improving both eye care practitioner and the general public’s knowledge of the need and ability to slow myopia progression clinically. We are looking forward to continuing to work with Oculus and all our sponsors in making evidence-based knowledge on myopia treatment and prevention freely available.”
Access all the latest IMI white papers and clinical summaries in up to twelve international languages here.
